Genprex (GNPX)
Develops REQORSA for lung cancer and GPX-002 for diabetes.
Something off on this page? Send us feedback.
Develops REQORSA gene therapy alongside approved lung-cancer treatments and GPX-002 for diabetes, a preclinical pancreatic-cell program. With no approved products or product revenue, development depends on external clinical, manufacturing, and research partners.
Develops REQORSA, a TUSC2 plasmid delivered intravenously through non-viral ONCOPREX lipid nanoparticles for lung cancer, alongside GPX-002, an AAV program intended to reprogram pancreatic cells in diabetes.
Pursues an add-on oncology strategy, pairing REQORSA with approved treatments in U.S. studies of EGFR-mutant non-small cell lung cancer and extensive-stage small cell lung cancer. The diabetes program remains preclinical, supported by University of Pittsburgh licenses and research collaborators.
Has no approved products, product-sales revenue, internal manufacturing facilities, or sales, marketing, and distribution experience. Clinical execution relies on trial sites, CROs, CDMOs, and third-party licenses.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.2M · Total debt $0 · Total assets $17.1M · Shareholders' equity $14.8M
- Revenue
- $0
- Operating income
- −$4.5M
- Net income
- −$4.4M
No dividends on record.
| Institutions26 holders · as of Mar 31, 2026 | 0.52% | 4.2K shares | |
| Insiders5 holders · as of Apr 15, 2026 | 0.47% | 3.9K shares | |
| Otherremainder | 99.01% | 811.6K shares |
819.7K company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (819.7K in the company's Sep 3, 2026 report, 504.9K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ryan M. ConferInsiderdirector, officer: President, CEO and CFO | 0.20% | 1,651 | Form 4filed Feb 27, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.19% | 33,372 | 13Fas of Mar 31, 2026 |
Mark Stanley BergerInsiderofficer: Chief Medical Officer | 0.12% | 986 | Form 4filed Feb 27, 2026 ↗ |
Manchester Financial IncInstitution | 0.11% | 20,000 | 13Fas of Mar 31, 2026 |
Mayflower Financial Advisors, LLCInstitution | 0.11% | 20,000 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 14, 2026 | Brent M. Longnecker | director | −18 | $1.23 |
- Johnson & Johnson
Approved post-osimertinib option in EGFR-mutant NSCLC.
- Amgen
First-line ES-SCLC maintenance program with a competing add-on.
- Vertex Pharmaceuticals
Advanced islet-cell replacement program for functional Type 1 diabetes.
- Fractyl Health
Closest pancreas-directed AAV gene-therapy program in Type 2 diabetes.
- Sana Biotechnology
Immune-evasive islet-cell approach to insulin-free Type 1 diabetes.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genprex | $3.51 | +0.29% | $1.8M | — | — | — | — |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Vertex Pharmaceuticals | $555.40 | −0.23% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Fractyl Health | $0.7077 | −0.03% | $112.1M | — | — | — | — |
| Sana Biotechnology | $3.95 | +1.28% | $1.08B | — | — | — | — |
| Median | 31.9 | 23.1 | 6.8 | +9.7% |